HAIKU

Project "HAIKU" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics.

We have developed RA-01, a novel drug product and a first line therapy for preventing and curing infectious diseases at ICUs based on the removal of inhibitory antibodies, which are used by bacteria to facilitate their infectivity. This new drug allows an immediate protection to patients admitted to ICU without generating antimicrobial resistance (AMR).

RA-01 will reduce public/private healthcare systems costs and improve a social benefit by freeing up hospital beds: €9,150 reduction in treatment costs, 7 days less at ICU and €15 k reduction in ICU costs.

Currently, our competitors are focused on new antibiotics and antibodies, so there are no other companies working in the removing of specific antibodies as a preventive and curative method for infectious diseases. The total potential market is estimated to be >13 million patients/year. From this market, will be target ICU patients at risk for prolonged stays: >4 million patients.

RemAb Therapeutics is a biotech company that develops a novel class of medicines by removing natural specific antibodies. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families affected by infectious diseases. Our drug molecule will be developed and de-risked through clinical trials-Ph2 and then licensed to pharma companies, to finalise their development and bring them to the market

By 2026 we expect to reach: a) 14% royalties’ rate on net sales with a RA-01 price to healthcare systems of €800-1000 (complete treatment); b) Total addressable market growing up to about €275 m; c) Net present value of €21.4 m (10% discount rate) and an IRR of 56%; d) Cumulative EBITDA over €23 m; e) 6% market share (240,000 patients); f) 15 newly created jobs.